STOCK TITAN

Kura Oncology (KURA) 10-K Filings

KURA NASDAQ

Here are the 10-K annual reports from Kura Oncology, Inc. (KURA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow KURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KURA filings page.

Rhea-AI Summary

Kura Oncology files its annual report highlighting a pivotal year in which the FDA approved KOMZIFTI (ziftomenib) on November 13, 2025 for adults with relapsed or refractory NPM1‑mutated AML who lack satisfactory alternatives. The company has transformed into a fully integrated commercial-stage organization, launching U.S. sales in November 2025 and co-promoting with Kyowa Kirin.

Kura estimates a U.S. market opportunity of about $350–$400 million annually for relapsed or refractory NPM1‑mutated AML and roughly $7.0 billion across frontline and relapsed or refractory AML. A broad menin inhibitor program spans multiple Phase 3 and Phase 1 combination trials in AML, plus an early program in GIST.

The company is also advancing next-generation menin inhibitors, including KO‑7246 for diabetes and cardiometabolic diseases, and darlifarnib, a next‑generation farnesyl transferase inhibitor in combinations across RCC, KRASG12C‑mutated NSCLC, CRC and PDAC. As of June 30, 2025, non‑affiliate equity had an aggregate market value of about $496.1 million, and 88,329,759 common shares were outstanding as of February 27, 2026.